Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

(2019) Kyung Hae Jung et al.   CLINICAL CANCER RESEARCH

EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

(2019) Lisa F. Licitra et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

(2018) Ranee Mehra et al.   BRITISH JOURNAL OF CANCER

Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs

(2018) Stefano Cavalieri et al.   CANCER TREATMENT REVIEWS

Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

(2018) Robert L. Ferris et al.   ORAL ONCOLOGY

Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors

(2018) Aaron M. Goodman et al.   JAMA Oncology

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Abstract LB-339: Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC)

(2018) Tanguy Y. Seiwert et al.   CANCER RESEARCH

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)

(2018) Tara C. Mitchell et al.   JOURNAL OF CLINICAL ONCOLOGY

Association of immune-related adverse events (irAEs) with improved response, progression-free survival, and overall survival for patients with metastatic head and neck cancer receiving anti-PD-1 therapy.

(2018) Corey Christian Foster et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and preliminary efficacy of talimogene laherparepvec (T-VEC) in combination (combo) with pembrobrolizumab (Pembro) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): A multicenter, phase 1b study (MASTERKEY-232).

(2018) Kevin J. Harrington et al.   JOURNAL OF CLINICAL ONCOLOGY

Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs standard of care (SOC) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in KEYNOTE-040.

(2018) Ezra E.W. Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune Checkpoint Inhibition in Head and Neck Cancer

(2018) Martin David Forster et al.   Frontiers in Oncology

1117TiPIMvoke010: Randomized phase III study of atezolizumab (atezo) as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN)

(2018) R Haddad et al.   ANNALS OF ONCOLOGY

1044OA phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results

(2018) E E W Cohen et al.   ANNALS OF ONCOLOGY

LBA8_PRKEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

(2018) B Burtness et al.   ANNALS OF ONCOLOGY

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy

(2018) Dan P. Zandberg et al.   EUROPEAN JOURNAL OF CANCER

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

(2018) Ezra E W Cohen et al.   LANCET

LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII

(2018) Takumi Maruhashi et al.   NATURE IMMUNOLOGY

Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy

(2018) Diane Evrard et al.   ORAL ONCOLOGY

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

(2018) Razvan Cristescu et al.   SCIENCE

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC

(2018) Lillian L. Siu et al.   JAMA Oncology

Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma

(2017) Jennifer D. Moy et al.   EUROPEAN JOURNAL OF CANCER

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial

(2017) Christopher R Heery et al.   LANCET ONCOLOGY

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

(2017) Kevin J Harrington et al.   LANCET ONCOLOGY

Tumor Mutational Burden and Response Rate to PD-1 Inhibition

(2017) Mark Yarchoan et al.   NEW ENGLAND JOURNAL OF MEDICINE

FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Containing Chemotherapy

(2017) Erin Larkins et al.   ONCOLOGIST

The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis

(2017) Emma J. de Ruiter et al.   OncoImmunology

Gene-expression profiling to predict responsiveness to immunotherapy

(2016) N B Jamieson et al.   CANCER GENE THERAPY

Investigational drugs for head and neck cancer

(2016) Paolo Bossi et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma

(2016) Adil I. Daud et al.   JOURNAL OF CLINICAL INVESTIGATION

Tumor-associated macrophages correlate with the clinicopathological features and poor outcomes via inducing epithelial to mesenchymal transition in oral squamous cell carcinoma

(2016) Yong Hu et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

(2016) Tanguy Y Seiwert et al.   LANCET ONCOLOGY

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

(2016) Vassiliki A. Boussiotis   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Amidst the excitement: A cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma

(2016) Shrujal S. Baxi et al.   ORAL ONCOLOGY

IL-8 promotes HNSCC progression on CXCR1/2-meidated NOD1/RIP2 signaling pathway

(2016) Leong-Perng Chan et al.   Oncotarget

Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma

(2016) Hae Su Kim et al.   Cancer Research and Treatment

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses

(2015) Norman Woller et al.   MOLECULAR THERAPY

Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer – Review of current data

(2015) Mark S. Swanson et al.   ORAL ONCOLOGY

Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data

(2015) Loris De Cecco et al.   Oncotarget

The Pekin duck programmed death-ligand 1: cDNA cloning, genomic structure, molecular characterization and mRNA expression analysis

(2014) Q. Yao et al.   International Journal of Immunogenetics

Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma

(2014) Joseph M. Curry et al.   SEMINARS IN ONCOLOGY

Genetic regulation and potentially therapeutic application of cancer-associated fibroblasts in oral cancer

(2013) Jingyi Wang et al.   JOURNAL OF ORAL PATHOLOGY & MEDICINE

The Tumor Microenvironment Contribution to Development, Growth, Invasion and Metastasis of Head and Neck Squamous Cell Carcinomas

(2013) Sittichai Koontongkaew   Journal of Cancer

Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma

(2012) Makoto Adachi et al.   ORAL ONCOLOGY

Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma

(2012) Jin Ye et al.   VIRCHOWS ARCHIV

Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer

(2010) K. Kian Ang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients

(2009) Jean-Pierre Pignon et al.   RADIOTHERAPY AND ONCOLOGY

Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity

(2008) R. J. Prestwich et al.   CLINICAL CANCER RESEARCH

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE